Compare Incyte Corporation (INCY) vs Oatly Group AB - ADR (OTLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Oatly Group AB - ADR — how do they compare? Incyte Corporation trades at $120.77 (market cap $24.54B), while Oatly Group AB - ADR trades at $13.26 (market cap $415.98M). The key difference: Incyte Corporation is far larger — about 59× Oatly Group AB - ADR's market cap, and Incyte Corporation is trading nearer its 52-week high, Oatly Group AB - ADR nearer its low. Which is the better fit depends on your goals.
| INCY | OTLY | |
|---|---|---|
Market Cap | $24.54B | $415.98M |
Sector | Health | Consumer Staples |
52-Week High | $129.93 | $18.54 |
52-Week Low | $81.61 | $8.03 |
Enterprise Value | $20.04B | $920.39M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.
Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.
OTLY trades at $13.18, up 0.46% on the day, with a bullish technical signal driven by moving averages and oversold RSI conditions. Revenue growth is accelerating, with Q2 2026 sales reaching $240.1 million and full-year guidance raised, though the company remains unprofitable with a net margin of -13.81%. Cash flow trends show reduced operational losses, but negative free cash flow persists.
The outlook hinges on OTLY's path to profitability; improved gross margins and cost controls offer potential upside, but high debt and sustained cash burn pose significant risks. Analyst sentiment is mixed with a 44.44% buy rating, reflecting optimism for growth against financial instability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Oatly Group AB - ADR
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, Icecreams, among others. It caters to Sweden, Germany, United Kingdom, Netherlands, North America, Finland, and other markets.
Read more on OTLY →
